This announcement is a separate document:
南京证券股份有限公司关于江苏诺泰澳赛诺生物制药股份有限公司新增2024年度日常关联交易预计事项的核查意见
Nanjing Securities Co., Ltd.'s verification opinion on the expected daily related party transactions of Jiangsu Novartis Ausino Bio-pharmaceutical Co., Ltd. in 2024.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.